Genetic variations in genes that control how methotrexate moves through cells appear to determine which children develop brain and nerve damage during leukemia treatment. A 2026 case-control study of 71 children found that transport genes accounted for 61% of genetic differences between children who experienced brain complications and those who didn’t, with two specific genes (ABCG2 and ABCC4) being the primary contributors. According to Gram Research analysis, these transport mechanisms may be more important than how the body breaks down the drug itself.
When children with acute lymphoblastic leukemia receive methotrexate, a powerful cancer-fighting drug, some develop serious brain and nerve problems while others don’t. Researchers studied 71 children to understand why. They found that differences in genes controlling how the body transports and processes methotrexate may explain who gets these dangerous side effects. According to Gram Research analysis, genes involved in moving the drug through cells appear more important than genes controlling how the body breaks it down. This discovery could help doctors predict which children are at higher risk before treatment starts.
Key Statistics
A 2026 case-control study of 71 pediatric leukemia patients found that transport-related genes accounted for 61.4% of all detected genetic variants associated with methotrexate-induced brain toxicity.
In the same study, genes ABCG2 and ABCC4 together harbored 18.4% of significant variants in overall methotrexate neurotoxicity cases and 20.6% and 17.6% respectively in stroke-like syndrome cases.
Pathway-level analysis in the 71-patient study showed statistically significant enrichment of transporter-related genetic variants in children with methotrexate brain toxicity compared to controls (p = 0.004).
The genetic pattern correlation between overall methotrexate neurotoxicity and stroke-like syndrome in the study was strong (Spearman’s correlation = 0.549, p = 0.022), suggesting shared genetic mechanisms.
The Quick Take
- What they studied: Why some children treated for blood cancer develop brain and nerve damage from their chemotherapy drug, while others don’t
- Who participated: 71 children with acute lymphoblastic leukemia from multiple hospitals: 34 who experienced brain side effects and 37 who didn’t
- Key finding: Children with certain genetic variations in genes that control drug transport had significantly more brain complications, with transport genes accounting for 61% of all genetic differences found
- What it means for you: Doctors may eventually use genetic testing before starting treatment to identify which children need closer monitoring or different dosing strategies, though this research is still early and needs confirmation in larger studies
The Research Details
Researchers compared two groups of children: those who developed brain and nerve problems from methotrexate and those who didn’t. They looked back at medical records from multiple hospitals across the country. For each child, they examined 17 different genes involved in how the body handles methotrexate, using advanced DNA sequencing technology to find genetic variations. This type of study, called a case-control design, is useful for identifying which genetic differences might cause a specific problem by comparing people who have the problem to similar people who don’t.
Understanding the genetic reasons why some children develop these serious side effects is crucial because it could allow doctors to predict risk before treatment begins. If doctors can identify high-risk children early, they might adjust doses, monitor more carefully, or choose alternative treatments. This personalized approach could prevent severe complications while still effectively treating the cancer.
This study has both strengths and limitations. The strength is that researchers used advanced genetic sequencing technology and studied multiple genes at once. The limitation is the small sample size of 71 children, which means the findings are preliminary. The researchers themselves note these are exploratory findings that need confirmation in larger studies before doctors can use them in practice. The study was conducted across multiple hospitals, which adds credibility.
What the Results Show
Transport genes, which control how methotrexate moves in and out of cells, showed the strongest connection to brain side effects. Children who experienced these complications had significantly more genetic variations in transport genes compared to those who didn’t. Specifically, two genes called ABCG2 and ABCC4 stood out as the main culprits, together accounting for about 18 to 21 percent of all significant genetic variations found. The pattern was especially clear in children who developed a specific type of brain complication called stroke-like syndrome, where blood flow to the brain is temporarily disrupted. In contrast, genes involved in how the body breaks down and uses folate (a B vitamin that methotrexate interferes with) did not show the same strong connection after accounting for multiple comparisons.
The research revealed that different types of brain complications may have different genetic causes. Children with focal neurological deficits, meaning problems in specific areas of the brain, showed particularly strong connections to transport gene variations. The genetic patterns between overall brain toxicity and stroke-like syndrome were strongly correlated, suggesting they may share similar underlying genetic mechanisms. Some genetic variations appeared protective, actually reducing risk, while others increased risk, indicating that the relationship between genes and side effects is complex and not simply one-directional.
Previous research has suggested that methotrexate side effects might be related to how the body processes the drug, but most studies focused on metabolism genes. This research shifts attention to transport genes as potentially more important. The finding that transport mechanisms matter more than metabolism pathways represents a meaningful shift in understanding and aligns with emerging evidence that how drugs enter and exit cells may be more critical than how they’re broken down.
The study included only 71 children, which is a small number for genetic research. Larger studies are needed to confirm these findings. The research was retrospective, meaning researchers looked back at past medical records rather than following children forward in time. The study was conducted in one country, so results may not apply to all populations. The researchers did not perform functional studies to prove that the genetic variations actually cause the side effects, only that they’re associated with them. These findings are exploratory and should not yet guide clinical decisions.
The Bottom Line
This research is too preliminary for doctors to use in clinical practice right now. However, it suggests that genetic testing of transport genes before starting methotrexate treatment may eventually help identify high-risk children. Parents and doctors should continue following current safety protocols and monitoring guidelines. Future research should confirm these findings in larger groups before any changes to treatment practices.
Parents of children newly diagnosed with acute lymphoblastic leukemia should be aware of this research direction, though it doesn’t change current treatment recommendations. Oncologists treating children with ALL should follow this research as it develops. Researchers studying cancer drug side effects should pay attention to transport gene pathways. Children already treated with methotrexate don’t need to take action based on this study.
This is basic research that may take 5 to 10 years to translate into clinical practice. Researchers first need to confirm findings in larger studies, then conduct functional studies to prove cause-and-effect, and finally develop and validate genetic tests. Only after all these steps would doctors potentially use genetic testing to guide treatment decisions.
Frequently Asked Questions
Can genetic testing predict which children will get brain damage from methotrexate?
Not yet. A 2026 study identified genetic variations linked to brain complications, but the research is too early for clinical use. Larger studies are needed to develop and validate a genetic test before doctors can use it to predict risk in individual children.
What genes cause methotrexate brain side effects in children?
Transport genes, particularly ABCG2 and ABCC4, appear most important based on a 71-patient study. These genes control how the drug moves in and out of cells. However, researchers emphasize these findings are exploratory and need confirmation in larger populations.
Should my child get genetic testing before starting leukemia treatment?
Current medical guidelines don’t recommend genetic testing for this purpose yet. This research is preliminary. Continue following your oncologist’s standard safety protocols and monitoring recommendations. Talk to your child’s doctor about this emerging research if you have concerns.
Are some children naturally protected from methotrexate brain damage?
Yes, according to a 2026 study, some genetic variations appear protective. For example, one variation in the ABCG2 gene was associated with reduced risk. However, other variations in the same gene increased risk, showing the relationship is complex.
How long until doctors can use this research to help patients?
Likely 5 to 10 years. Researchers must first confirm findings in larger studies, prove the genetic variations actually cause the problem, develop a clinical test, and validate it in practice before doctors can use genetic information to guide treatment decisions.
Want to Apply This Research?
- For families of children undergoing ALL treatment, track weekly neurological symptoms including headaches, balance problems, vision changes, weakness, or numbness using a simple daily checklist, noting severity on a 1-10 scale
- Create a medication safety log that records methotrexate doses, dates, and any neurological symptoms that appear within 48 hours of treatment, making it easy to share patterns with the medical team
- Maintain a long-term symptom journal throughout and after treatment, documenting any delayed neurological effects, which helps doctors understand individual response patterns and informs future treatment decisions
This research is exploratory and preliminary. The findings have not yet been confirmed in larger studies and should not guide clinical treatment decisions. Parents and patients should continue following current medical guidelines and consulting with their oncology team. Genetic testing for methotrexate sensitivity is not yet available or recommended for clinical use. This article is for educational purposes only and does not replace professional medical advice. Always discuss new research findings with your child’s healthcare provider before making any changes to treatment or monitoring.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.